Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 PRIMARY RESEARCH
  • FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
  • 2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
  • FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
• 2.2 DATA TRIANGULATION APPROACH
  • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.2.1 SECONDARY RESEARCH
  • 2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
• 2.3 RESEARCH LIMITATIONS
• 2.4 RISK ASSESSMENT
• 2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
  • 2.5.1 SUPPLY SIDE
  • 2.5.2 DEMAND SIDE
    • 2.5.2.1 Insights from primary experts

3 EXECUTIVE SUMMARY

• FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
• FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE 2022 VS. 2027 (USD MILLION)
• FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE BLADDER TREATMENT MARKET

4 PREMIUM INSIGHTS

• 4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
  • FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
• 4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
  • FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
• 4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
  • FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2027
• 4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
  • 5.2.1 MARKET DRIVERS
    • 5.2.1.1 Rising prevalence of overactive bladder syndrome
    • 5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
  • FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
    • 5.2.1.3 Development and use of innovative intravesical therapies
    • 5.2.1.4 Growing R&D investments and the launch of novel therapies in the coming years
  • 5.2.2 MARKET RESTRAINTS
    • 5.2.2.1 Frequent product recalls
    • 5.2.2.2 Increased side effects of anticholinergic drugs
  • 5.2.3 MARKET OPPORTUNITIES
    • 5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
  • 5.2.4 MARKET CHALLENGES
    • 5.2.4.1 Social stigma and lack of awareness about OAB
• 5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
  • FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
• 5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
• 5.6 VALUE CHAIN ANALYSIS
  • FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
• 5.7 SUPPLY CHAIN ANALYSIS
  • FIGURE 18 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
• 5.8 ECOSYSTEM ANALYSIS
  • FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
  • FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
• 5.9 REGULATORY SCENARIO
  • 5.9.1 PHARMACEUTICAL INDUSTRY
    • 5.9.1.1 Regulatory requirements
      • 5.9.1.1.1 EU regulations
      • 5.9.1.1.2 US regulations
  • 5.9.2 MEDICAL DEVICE INDUSTRY
    • 5.9.2.1 Regulatory requirements
      • 5.9.2.1.1 EU regulations
      • 5.9.2.1.2 US regulations
  • TABLE 2 LIST OF REGULATORY AUTHORITIES
• 5.10 TECHNOLOGY ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS IN 2022-2023
  • TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF CONFERENCES AND EVENTS
• 5.12 PATENT ANALYSIS
  • FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT FROM NEW ENTRANTS
  • 5.13.2 THREAT FROM SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 DEGREE OF COMPETITION
• 5.14 PRICING ANALYSIS
  • TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS (GENERICS)
  • TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
  • TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
  • FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
• 5.16 PIPELINE ANALYSIS
  • FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS

6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE

• 6.1 INTRODUCTION
  • TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
• 6.2 MIRABEGRON
  • 6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
  • TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020-2027 (USD MILLION)
• 6.3 ANTICHOLINERGICS
  • TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • 6.3.1 SOLIFENACIN
    • 6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence-a key factor driving market growth
  • TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.2 OXYBUTYNIN
    • 6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
  • TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.3 FESOTERODINE
    • 6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
  • TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.4 DARIFENACIN
    • 6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
  • TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.5 TOLTERODINE
    • 6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
  • TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.6 TROSPIUM
    • 6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
  • TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020-2027 (USD MILLION)
  • 6.3.7 OTHER ANTICHOLINERGICS
  • TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
• 6.4 BOTOX
  • 6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
  • TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020-2027 (USD MILLION)
• 6.5 NEUROMODULATION
  • 6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
  • TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020-2027 (USD MILLION)
• 6.6 OTHER TREATMENTS
  • TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020-2027 (USD MILLION)

7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE

• 7.1 INTRODUCTION
  • TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
• 7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
  • 7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
  • TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
• 7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
  • TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 7.3.1 PARKINSON'S DISEASE
    • 7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson's disease to drive market growth
  • TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON'S DISEASE, BY REGION, 2020-2027 (USD MILLION)
  • 7.3.2 STROKES
    • 7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
  • TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020-2027 (USD MILLION)
  • 7.3.3 MULTIPLE SCLEROSIS
    • 7.3.3.1 Favorable reimbursement policies to support the growth of the OAB treatment market for MS
  • TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020-2027 (USD MILLION)
  • 7.3.4 SPINAL CORD INJURIES
    • 7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
  • TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020-2027 (USD MILLION)
  • 7.3.5 OTHER DISORDERS
  • TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020-2027 (USD MILLION)

8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION

• 8.1 INTRODUCTION
  • TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
• 8.2 NORTH AMERICA
  • FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
  • TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.2.1 US
    • 8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
  • TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.2.2 CANADA
    • 8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
  • TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
• 8.3 EUROPE
  • TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.1 GERMANY
    • 8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
  • TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.2 UK
    • 8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth in the OAB market
  • TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
  • TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.3 FRANCE
    • 8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
  • TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
  • TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.4 ITALY
    • 8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
  • TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.5 SPAIN
    • 8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
  • TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3.6 REST OF EUROPE
  • TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
• 8.4 ASIA PACIFIC
  • FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
  • TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4.1 JAPAN
    • 8.4.1.1 Advancements in treatment options to fuel growth in the market in Japan
  • TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4.2 CHINA
    • 8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
  • TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4.3 INDIA
    • 8.4.3.1 India is the world's largest producer of generic drugs- a key factor driving market growth
  • TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4.4 AUSTRALIA
    • 8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia-a major factor supporting the growth of this market
  • TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4.5 REST OF ASIA PACIFIC
  • TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
• 8.5 LATIN AMERICA
  • TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.5.1 BRAZIL
    • 8.5.1.1 Increased use of overactive bladder drugs in the country to drive growth in the market
  • FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004-2050
  • TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.5.2 MEXICO
    • 8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
  • TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.5.3 REST OF LATIN AMERICA
  • TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
• 8.6 MIDDLE EAST & AFRICA
  • 8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
  • TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
  • TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
  • FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
• 9.3 MARKET SHARE ANALYSIS
  • FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
  • TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
• 9.4 REVENUE ANALYSIS
  • FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
• 9.5 COMPANY EVALUATION QUADRANT
  • 9.5.1 STARS
  • 9.5.2 EMERGING LEADERS
  • 9.5.3 PERVASIVE PLAYERS
  • 9.5.4 PARTICIPANTS
  • FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2021
• 9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
  • 9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
  • TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
  • TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
  • TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
• 9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
  • 9.7.1 PROGRESSIVE COMPANIES
  • 9.7.2 STARTING BLOCKS
  • 9.7.3 RESPONSIVE COMPANIES
  • 9.7.4 DYNAMIC COMPANIES
  • FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
  • 9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
• 9.8 COMPETITIVE SCENARIO AND TRENDS
  • 9.8.1 PRODUCT LAUNCHES & APPROVALS
  • TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-MAY 2022
  • 9.8.2 DEALS
  • TABLE 131 DEALS, JANUARY 2019-MAY 2022

10 COMPANY PROFILES

• 10.1 KEY PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 10.1.1 ASTELLAS PHARMA INC.
• TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
• FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
• 10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
• TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
• FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
• 10.1.3 PFIZER INC.
• TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
• FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
• 10.1.4 ABBVIE INC.
• TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
• FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
• 10.1.5 VIATRIS INC.
• TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
• FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
• 10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
• TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
• FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
• 10.1.7 JOHNSON & JOHNSON SERVICES, INC.
• TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
• FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
• 10.1.8 ENDO PHARMACEUTICALS INC.
• TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
• FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
• 10.1.9 LUPIN
• TABLE 140 LUPIN: BUSINESS OVERVIEW
• FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
• 10.1.10 AMNEAL PHARMACEUTICALS LLC
• TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
• FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
• 10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
• TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
• FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
• 10.1.12 GLENMARK
• TABLE 143 GLENMARK: BUSINESS OVERVIEW
• FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
• 10.1.13 MACLEODS PHARMACEUTICALS LTD.
• TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
• FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
• 10.1.14 MEDTRONIC
• TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
• FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
• 10.1.15 AJANTA PHARMA
• TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
• FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
• 10.1.16 GRANULES INDIA LIMITED
• TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
• FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
• 10.2 OTHER PLAYERS
  • 10.2.1 UROVANT SCIENCES
  • TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
  • 10.2.2 APOTEX INC.
  • TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
  • 10.2.3 LABORIE
  • TABLE 150 LABORIE: BUSINESS OVERVIEW
  • 10.2.4 INTAS PHARMACEUTICALS LTD.
  • TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
  • 10.2.5 BAYER AG
  • TABLE 152 BAYER AG: BUSINESS OVERVIEW
  • 10.2.6 MEDYTOX
  • TABLE 153 MEDYTOX: BUSINESS OVERVIEW
  • 10.2.7 ALTHERX PHARMACEUTICALS
  • TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
  • 10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
  • TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
  • 10.2.9 HUGEL, INC.
  • TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

• 11.1 DISCUSSION GUIDE
• 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 11.3 AVAILABLE CUSTOMIZATIONS
• 11.4 RELATED REPORTS
• 11.5 AUTHOR DETAILS